Abstract
Introduction: It is unknown if treatment with rt-PA in mild acute ischemic stroke (MIS) is associated with improvement in long term cognition. Methods: Forty-five patients with suspected acute mild stroke or transient ischemic attacks with NIHSS ≤6 were enrolled in a prospective cohort. Cognitive testing was performed within 24 h of symptom onset. Follow-up assessment was performed at Day 90 on 25 patients. Prestroke baseline cognition was based on age, years of education (YrE), history of cognitive impairment, and the Fazekas score. Results: Eighty-five percent patients with suspected MIS or TIA showed cognitive abnormalities within 24 h of onset. There was no significant difference in age, sex, Fazekas score, or YrE between rt-PA versus No-rt-PA groups (N = 8 vs. 17).Two sample t-test for change in performance in the WMS-III sub-tests (follow-up – baseline) ± SD, indicated a difference between rt-PA 0.74 ± 0.77 and no-rt-PA groups -0.02 ± 0.83 (P = 0.044). Logistic regression for predicting normal status using the mental control subtest, at follow-up showed an OR 8.96, CI 0.98–82.12 (P = 0.05) favoring the rt-PA group. Improvement in Mental Control at 90 days occurred in patients with low white matter disease compared to high white matter disease, 0.60 ± 0.46 (P = 0.048). A statistical trend was observed and suggested an improvement on SDMT and Trail Making tests, 1.43 ± 0.8 (P = 0.077). Conclusion: Suspected MIS and TIA patients have cognitive impairment within 24 h of onset. rt-PA administration might be associated with improvement on some cognitive tests at 90 days.
Original language | English (US) |
---|---|
Pages (from-to) | 466-474 |
Number of pages | 9 |
Journal | Annals of Clinical and Translational Neurology |
Volume | 6 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2019 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Cognitive Dysfunction/etiology
- Cohort Studies
- Female
- Humans
- Ischemic Attack, Transient/complications
- Male
- Middle Aged
- Prospective Studies
- Stroke/complications
- Time Factors
- Tissue Plasminogen Activator/therapeutic use
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology